564 related articles for article (PubMed ID: 9187119)
21. Structural modification of serum vitamin D3-binding protein and immunosuppression in AIDS patients.
Yamamoto N; Naraparaju VR; Srinivasula SM
AIDS Res Hum Retroviruses; 1995 Nov; 11(11):1373-8. PubMed ID: 8573395
[TBL] [Abstract][Full Text] [Related]
22. β-Galactosidase treatment is a common first-stage modification of the three major subtypes of Gc protein to GcMAF.
Uto Y; Yamamoto S; Mukai H; Ishiyama N; Takeuchi R; Nakagawa Y; Hirota K; Terada H; Onizuka S; Hori H
Anticancer Res; 2012 Jun; 32(6):2359-64. PubMed ID: 22641675
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor, GcMAF.
Yamamoto N; Suyama H; Yamamoto N
Transl Oncol; 2008 Jul; 1(2):65-72. PubMed ID: 18633461
[TBL] [Abstract][Full Text] [Related]
24. Case Report: GcMAF Treatment in a Patient with Multiple Sclerosis.
Inui T; Katsuura G; Kubo K; Kuchiike D; Chenery L; Uto Y; Nishikata T; Mette M
Anticancer Res; 2016 Jul; 36(7):3771-4. PubMed ID: 27354653
[TBL] [Abstract][Full Text] [Related]
25. A defect in the inflammation-primed macrophage-activation cascade in osteopetrotic rats.
Yamamoto N; Lindsay DD; Naraparaju VR; Ireland RA; Popoff SN
J Immunol; 1994 May; 152(10):5100-7. PubMed ID: 8176226
[TBL] [Abstract][Full Text] [Related]
26. Identification of the serum factor required for in vitro activation of macrophages. Role of vitamin D3-binding protein (group specific component, Gc) in lysophospholipid activation of mouse peritoneal macrophages.
Yamamoto N; Homma S; Millman I
J Immunol; 1991 Jul; 147(1):273-80. PubMed ID: 2051023
[TBL] [Abstract][Full Text] [Related]
27. Chemotherapeutic potential of two gallic acid derivative compounds from leaves of Casearia sylvestris Sw (Flacourtiaceae).
Da Silva SL; Chaar Jda S; Yano T
Eur J Pharmacol; 2009 Apr; 608(1-3):76-83. PubMed ID: 19222998
[TBL] [Abstract][Full Text] [Related]
28. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
29. Vitamin D3 binding protein required for in vitro activation of macrophages after alkylglycerol treatment of mouse peritoneal cells.
Yamamoto N; Homma S; Haddad JG; Kowalski MA
Immunology; 1991 Nov; 74(3):420-4. PubMed ID: 1769691
[TBL] [Abstract][Full Text] [Related]
30. Is α-N-acetylgalactosaminidase the key to curing cancer? A mini-review and hypothesis.
Saburi E; Tavakol-Afshari J; Biglari S; Mortazavi Y
J BUON; 2017; 22(6):1372-1377. PubMed ID: 29332325
[TBL] [Abstract][Full Text] [Related]
31. NTP Toxicology and Carcinogenesis Studies of C.I. Direct Blue 218 (CAS No. 28407-37-6) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Feb; 430():1-280. PubMed ID: 12616301
[TBL] [Abstract][Full Text] [Related]
32. Deglycosylation of serum vitamin D3-binding protein by alpha-N-acetylgalactosaminidase detected in the plasma of patients with systemic lupus erythematosus.
Yamamoto N; Naraparaju VR; Moore M; Brent LH
Clin Immunol Immunopathol; 1997 Mar; 82(3):290-8. PubMed ID: 9073553
[TBL] [Abstract][Full Text] [Related]
33. Antitumour activity of [1,2-di(cyclopentadienyl)-1,2-di(p-N,N-dimethylaminophenyl)-ethanediyl] titanium dichloride in xenografted Ehrlich's ascites tumour.
Valadares MC; Ramos AL; Rehmann FJ; Sweeney NJ; Strohfeldt K; Tacke M; Queiroz ML
Eur J Pharmacol; 2006 Mar; 534(1-3):264-70. PubMed ID: 16513106
[TBL] [Abstract][Full Text] [Related]
34. Vitamin D3-binding protein as a precursor for macrophage activating factor in the inflammation-primed macrophage activation cascade in rats.
Yamamoto N; Naraparaju VR
Cell Immunol; 1996 Jun; 170(2):161-7. PubMed ID: 8660814
[TBL] [Abstract][Full Text] [Related]
35. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
Marsman D
Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
[TBL] [Abstract][Full Text] [Related]
36. A designed glycoprotein analogue of Gc-MAF exhibits native-like phagocytic activity.
Bogani F; McConnell E; Joshi L; Chang Y; Ghirlanda G
J Am Chem Soc; 2006 Jun; 128(22):7142-3. PubMed ID: 16734450
[TBL] [Abstract][Full Text] [Related]
37. A novel assay system for macrophage-activating factor activity using a human U937 cell line.
Ishikawa M; Inoue T; Inui T; Kuchiike D; Kubo K; Uto Y; Nishikata T
Anticancer Res; 2014 Aug; 34(8):4577-81. PubMed ID: 25075102
[TBL] [Abstract][Full Text] [Related]
38. Chemotherapeutic potential of the volatile oils from Zanthoxylum rhoifolium Lam leaves.
da Silva SL; Figueiredo PM; Yano T
Eur J Pharmacol; 2007 Dec; 576(1-3):180-8. PubMed ID: 17716654
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of Ehrlich ascites tumor cell growth by Griffonia simplicifolia I lectin in vivo.
Eckhardt AE; Malone BN; Goldstein IJ
Cancer Res; 1982 Aug; 42(8):2977-9. PubMed ID: 7093946
[TBL] [Abstract][Full Text] [Related]
40. Physiological disposition of pentobarbital in tumor-bearing mice.
Beck WT; Mandel HG; Fabro S
Cancer Res; 1975 May; 35(5):1333-40. PubMed ID: 1120316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
